{"database": "lobbying", "table": "lobbying_activities", "rows": [[834376, "5f91dc15-fdf6-447f-bfbd-f8fac7f7f283", "Q3", "FIERCE, ISAKOWITZ & BLALOCK", 44812, "COALITION FOR A COMPETITIVE PHARMACEUTICAL MARKET", 2009, "third_quarter", "PHA", "Generic Biologics:\n-S726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act\n-H.R.1548: Pathway for Biosimilars Act\n-S.1679 Affordable Health Choices Act\nAmericas Health Future Act of 2009\n-Biosimilar Reimbursement Utilization Equity Amendment -Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2009-10-18T18:50:55-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["834376"], "units": {}, "query_ms": 7.269952911883593, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}